# MBrace Therapeutics

**Canonical:** https://apis.io/providers/mbrace-therapeutics/  
**Website:** https://mbracetrx.com/  
**APIs profiled:** 9

MBrace Therapeutics is a privately held, clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) against novel oncology targets. Co-founded by Renata Pasqualini, Ph.D. and Isan Chen, MD, the company builds its pipeline on SPARTA, an in vivo antibody selection and target discovery process it uses to find ADC targets that conventional in vitro discovery misses. Its lead candidate MBRC-101 is an anti-EphA5 monomethyl auristatin E (MMAE) antibody-drug conjugate in a multi-centre, open-label Phase 1/1b dose-finding, safety and pharmacokinetic study in advanced refractory solid tumours; MBRC-201 is in Phase 2, MBRC-301 is in IND-enabling studies against solid tumours, and MBRC-401 is in discovery. MBrace emerged from stealth in November 2023 with an $85 million Series B led by TPG through TPG Life Sciences Innovations, alongside Avidity Partners, Blue Owl Capital, Venrock and Alta Partners, bringing total capital raised to $110 million. MBRC-101 was named Most Promising Clinical Candidate at the 11th Annual World ADC Awards. MBrace Therapeutics runs no developer program and publishes no product API, developer portal, API reference or SDK. The only machine-readable surface reachable without credentials is the WordPress REST content API behind mbracetrx.com, catalogued here — notable because the company registered five of its own custom post types, so its board, executive committee, founders, named investors and scientific advisory board are all published as structured JSON rather than only as rendered HTML.

## Kin Score — 30.0 / 100 (thin)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 30.0).

| Facet | Score |
|---|---|
| Discoverability | 74.1 |
| Contract Quality | 52.6 |
| Governance | 4.5 |
| Contract Governance | 4.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 13.7 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 21.8 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | bearer |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Self-serve signup — onboarding: self-serve, pricing: unknown, trial: no (confidence: medium).

## APIs (9)

- **MBrace Therapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **MBrace Therapeutics Media API** — Media library (224 attachments at harvest time).
- **MBrace Therapeutics News API** — Company news archive — press releases, scientific presentations and publications (8 published at harvest time, spanning November 2023 through July 2025).
- **MBrace Therapeutics Oembed API** — oEmbed 1.0 provider endpoint for mbracetrx.com URLs.
- **MBrace Therapeutics Pages API** — Corporate site pages (12 published at harvest time).
- **MBrace Therapeutics People API** — The five company-specific custom post types MBrace Therapeutics registered for its own governance and backer disclosures: board members, executive committee, founders, investors...
- **MBrace Therapeutics Search API** — Cross-content search across every published object on the deployment (76 searchable objects at harvest time).
- **MBrace Therapeutics Taxonomy API** — Category and tag terms. Four categories are registered; the post_tag taxonomy is registered but empty.
- **MBrace Therapeutics Users API** — Post authors exposed by the users collection (3 at harvest time).

## Security (2)

- **Mbrace Therapeutics Authentication** — 2 schemes
- **Mbrace Therapeutics Domain Security** — TLSv1.3 · DMARC

## Plans (1)

- **Mbrace Therapeutics Plans Pricing**

## Tags

Company, Biotechnology, Pharmaceuticals, Oncology, Antibody-Drug Conjugates, Drug Discovery, Clinical Trials, Life Sciences, Precision Medicine, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/mbrace-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.